1. Outcomes of cutaneous surgery for nonmelanoma skin cancer in patients with different Fitzpatrick skin types: A nationwide, multicenter, prospective study.
- Author
-
Nadir U, Yi MD, Koza E, Shi VJ, Dave L, Hisham FI, Maisel-Campbell A, Lin KA, Ibrahim SA, Kang BY, Anvery N, Dirr MA, Christensen RE, Riley JM, Kundu RV, Aylward JL, Bari O, Bhatti H, Bolotin D, Cherpelis BS, Cohen JL, Condon S, Farhang S, Firoz B, Garrett AB, Geronemus RG, Golda NJ, Humphreys TR, Hurst EA, Jacobson OH, Jiang SB, Karia PS, Kimyai-Asadi A, Kouba DJ, Council ML, Le M, MacFarlane DF, Maher IA, Miller SJ, Moioli EK, Morrow M, Neckman J, Peterson SR, Poblete-Lopez C, Prather CL, Ranario JS, Rubin AG, Swanson AM, Urban C, Xu YG, Pearlman R, Cahn BA, Yoo S, Harikumar V, Weil A, Schaeffer M, Iyengar S, Poon E, and Alam M
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mohs Surgery, Prospective Studies, Skin Pigmentation, Treatment Outcome, Carcinoma, Basal Cell surgery, Carcinoma, Basal Cell pathology, Carcinoma, Squamous Cell surgery, Carcinoma, Squamous Cell pathology, Skin Neoplasms surgery, Skin Neoplasms pathology
- Abstract
Competing Interests: Conflicts of interest Dr Bolotin reported serving as principal investigator on a clinical trial sponsored by Replimune outside the submitted work. Dr Cohen reported serving as a clinical investigator, consultant, or speaker or trainer for Accure, Allergan, Almirall/Athenex, Avuta, Biofrontera Bioscience, Biopelle, Brickell Biotech, Croma, Elta, Endo Pharmaceuticals, Ferndale, Galderma, InMode, IntraDerm, Lutronic, Merz, Novan, PCA, Pulse Biosciences, Raziel, Recros Medica, Revance, Revision, Sciton, and Sente outside the submitted work. Dr Council reported receiving personal fees from Sanofi Genzyme Regeneron, AbbVie, and Castle Biosciences outside the submitted work. Dr Riley has served as an advisory board member for Novartis Pharmaceuticals. The other authors have no conflicts of interest to declare.
- Published
- 2024
- Full Text
- View/download PDF